Preserving the mind: key takeaways from AAN 2022

AAN 2022 highlighted cutting-edge research in neurology and provided opportunities for networking within the neurology community. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from advances for traumatic brain injury to the future of AI and neurology.

Continue Reading Preserving the mind: key takeaways from AAN 2022

The future of MS biomarkers: key takeaways from ACTRIMS 2022

ACTRIMS 2022 highlighted novel scientific discoveries for multiple sclerosis (MS), with a focus on MS biomarkers. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from better, novel treatments to the potential of enhanced AI-based neuroimaging for improved patient management.

Continue Reading The future of MS biomarkers: key takeaways from ACTRIMS 2022

Meet the Team: Peter Ngum, Clinical Application Specialist

In the third edition of our “Meet the Team” blog series, we talk to Peter Ngum, one of Combinostics’ Clinical Application Specialists, about his academic and industry experience, what he loves about his role, and some fascinating conferences he’s attended recently.

Continue Reading Meet the Team: Peter Ngum, Clinical Application Specialist

Early detection and differentiation of dementias: with AI, vast amounts of data are an asset, not a burden

Although detection of and differentiation among the various types of dementia remain challenging for clinicians, technological advances such as artificial intelligence (AI) and machine learning (ML) can help.

Continue Reading Early detection and differentiation of dementias: with AI, vast amounts of data are an asset, not a burden

Meet the Team: Jin Gong, Imaging Scientist

In our second post of the “Meet the Team” series, we sat down with Combinostics Imaging Scientist Jin Gong, to chat about her degrees, her personal connection with Alzheimer’s disease (AD), and her love of travel, gaming, and great bargains.

Continue Reading Meet the Team: Jin Gong, Imaging Scientist

Can AI help with patient selection for Aduhelm and other new disease-modifying drugs for Alzheimer’s disease?

Drug development and selection of drugs for patients in clinical practice for Alzheimer's disease are challenged by many factors, including patient heterogeneity. AI had the potential to help select patients for whom a drug is most suitable — in trials and in practice.

Continue Reading Can AI help with patient selection for Aduhelm and other new disease-modifying drugs for Alzheimer’s disease?